[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-obstructive-pulmonary-disease-copd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-obstructive-pulmonary-disease-copd":668},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,112,0,25,[9,46,75,101,130,160,183,211,247,280,307,352,377,401,426,448,469,487,511,535,558,583,607,629,652],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100652902","tcm-cohort-for-elderly-copd-100652902",false,"NCT07780682","TCM Cohort for Elderly COPD","A Prospective Traditional Chinese Medicine Cohort Study of Chronic Obstructive Pulmonary Disease in the Elderly","Inclusion Criteria:\n\n* Patients diagnosed with COPD;\n* Age ≥ 60 years old;\n* Voluntary participation in this study, and sign the informed consent form.\n\nExclusion Criteria:\n\n* Patients with various mental illnesses or other conditions that prevent normal communication;\n* Patients with a history of pulmonary surgery, such as lung volume reduction surgery or lung transplantation;\n* Patients with confirmed human immunodeficiency virus infection or acquired immunodeficiency syndrome.",true,"ALL","60 Years",{"count":21,"type":22},2386,"ESTIMATED","52 Weeks","OBSERVATIONAL","This study evaluates the real-world clinical efficacy of traditional Chinese medicine (TCM) in elderly Chronic obstructive pulmonary disease (COPD) patients and explores syndrome characteristics and their associations with biomarkers.",[27],"Chronic Obstructive Pulmonary Disease (COPD)",[29,30,31,32],"Chronic Obstructive Pulmonary Disease in the Elderly","Cohort Study","Traditional Chinese Medicine Syndromes","Biomarkers","NOT_YET_RECRUITING","2026-08-19",{"date":36,"type":37},"2026-08-21","ACTUAL",{"date":39,"type":22},"2026-08-20",{"date":41,"type":22},"2030-02-28",{"name":43,"class":44},"Henan University of Traditional Chinese Medicine","OTHER",1,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100643871","phase-1-a-study-of-the-safety-tolerability-pharmacokinetics-and-efficacy-of-kit2014-in-patients-with-moderate-to-severe-copd-100643871","NCT07668518","A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of KIT2014 in Patients With Moderate to Severe COPD","A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Dose Ranging, Phase 1b\u002F2a Study to Investigate the Safety, Tolerability, Pharmacokinetics and Early Efficacy of Inhaled KIT2014 Over 7 Days of Treatment in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease","Inclusion Criteria:\n\n* Must have given written informed consent before any study-related activities are performed and must be able to understand the full nature and purpose of the study, including possible risks and adverse effects\n* Adult males and females, 40 to 80 years of age (inclusive) at screening.\n* Current or former cigarette smokers with a ≥10 pack-year smoking history\n* Established physician diagnosis of COPD with associated symptoms defined by the GOLD guidelines for ≥ 12 months of screening.\n* FEV1 post-bronchodilator of 40% to 80% of predicted normal at Screening\n* Current symptoms of COPD, including bronchitis and\u002For dyspnoea on moderate exertion at screening.\n\nExclusion Criteria:\n\n* History of life-threatening COPD\n* Chronic obstructive pulmonary disease exacerbation requiring oral or parenteral corticosteroids or hospitalisation within 3 months of Screening\n* Other clinically active, physician diagnosed moderate to severe respiratory disorders that could interfere with study assessments or confound results (e.g., asthma, bronchiectasis, pulmonary fibrosis, interstitial lung diseases, bronchiolitis obliterans, lung cancer, cor pulmonale, pulmonary hypertension, uncontrolled sleep apnoea, active tuberculosis).\n\nOther inclusion\u002Fexclusion eligibility criteria apply.","40 Years","80 Years",{"count":56,"type":22},36,"INTERVENTIONAL",[59,60],"PHASE1","PHASE2","Study investigating the safety, tolerability, pharmacokinetics and early efficacy with KIT2014 over 7 days of treatment in moderate to severe chronic obstructive pulmonary disease patients.",[27],"RECRUITING","2026-08-14",{"date":66,"type":37},"2026-08-18",{"date":68,"type":37},"2026-08-05",{"date":70,"type":22},"2027-07-31",{"name":72,"class":73},"Kither Biotech Srl","INDUSTRY",2,{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":57,"phases":84,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":45},"100638665","investigation-of-the-effect-of-structured-energy-conservation-techniques-training-on-copd-patients-100638665","NCT07581132","Investigation of the Effect of Structured Energy Conservation Techniques Training on COPD Patients","Investigation of the Effects of Structured Energy Conservation Techniques Training on Activities of Daily Living, Fatigue, and Exercise Capacity in COPD Patients","Inclusion Criteria:\n\n* Patients who have been admitted to the pulmonary diseases ward or have applied to the pulmonary diseases outpatient clinic,\n* Patients diagnosed with COPD,\n* Patients in category E of the GOLD A, B, E classification (patients experiencing more than 2 moderate exacerbations or having multiple hospitalizations) (GOLD, 2025)\n* Patients over 40 years of age (Adeloye et al, 2015).\n* Patients who will continue their health check-ups at the Isparta City Hospital Pulmonology Outpatient Clinic,\n* Patients who agree to participate in the study,\n* Patients or at least one of their relatives who can read and write,\n* Patients or at least one of their relatives who does not have communication problems will be included in the study.\n\nExclusion Criteria:\n\n* Patients with serious orthopedic problems that may have a significant impact on daily activities,\n* Patients with progressive neuromuscular disease,\n* Patients who have experienced unstable angina pectoris or myocardial infarction within the last month,\n* Patients living alone,\n* Patients in groups A and B of the GOLD ABE classification will not be included. For patients in group A, mMRC 0-1, CAT\\\u003C10 are used as criteria; for patients in group B, mMRC≥2, CAT≥10 are used as criteria (GOLD, 2025).",{"count":83,"type":22},70,[85],"NA","Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung disease characterized by chronic respiratory symptoms (dyspnea, cough, sputum production, and\u002For exacerbations) due to persistent, often progressive airflow obstruction resulting from abnormalities in the airways (bronchiolitis, bronchitis) and\u002For alveoli (emphysema). COPD is a multifaceted disease that is not limited to respiratory symptoms but also negatively affects individuals' functional capacity, physical endurance, and participation in daily living activities. Common symptoms include shortness of breath (dyspnea) and a significant feeling of fatigue; this can lead to decreased exercise capacity, limitations in daily living activities, and ultimately dependence over time. Therefore, in the treatment of COPD, not only drug therapy but also interventions aimed at symptom control and improving functional capacity are becoming increasingly important. Energy conservation techniques, included in pulmonary rehabilitation programs, are based on the view that dyspnea occurs most intensely during daily living activities, and that performing these activities in an energy-conserving manner will result in less dyspnea. Energy conservation techniques are one of the trainings given to improve symptom management in COPD patients. Disease symptoms can increase in COPD patients during tasks such as washing hair, drying hair, shaving, reaching, bending, lifting, carrying, pushing, and pulling weights. When appropriate body mechanics and tools that facilitate tasks are used, the amount of energy required during these tasks decreases. In this way, it is thought that patients will be more active in their daily living activities. Breathing exercises are also a component of pulmonary rehabilitation and support the increase of respiratory muscle function and exercise tolerance. Accordingly, it is thought that structured energy conservation techniques training can improve daily living activities, fatigue, and exercise capacity in COPD patients. This research will be conducted as a pre-test-post-test, single-blind, randomized controlled trial to examine the effect of structured energy conservation techniques training on daily living activities, fatigue, and exercise capacity in COPD patients.",[27],[89,90,91],"Activities of Daily Living","COPD","Energy Conservation","2026-08-10",{"date":94,"type":37},"2026-08-12",{"date":96,"type":22},"2026-10-10",{"date":98,"type":22},"2027-01-10",{"name":100,"class":44},"Akdeniz University",{"id":102,"slug":103,"hasResults":12,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":57,"phases":111,"briefSummary":112,"conditions":113,"keywords":114,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":129},"100599303","phase-2-a-study-to-investigate-the-effect-of-azd6793-in-participants-with-moderate-to-very-severe-chronic-obstructive-pulmonary-disease-100599303","NCT07082738","A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease","A Multicentre, Parallel-group, Phase IIb, Randomised, Double-blind, Placebo-controlled, 3-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO)","PRESTO","Inclusion Criteria:\n\n* Participant must be ≥40 years of age at the time of signing the informed consent.\n* Documented primary diagnosis of COPD for at least 12 months prior to enrolment.\n* Pre-BD FEV1\u002FFVC \\\u003C 0.7 at Visit 1 and pre- and post-BD FEV1\u002FFVC \\\u003C 0.7, and post-BD FEV1 ≥ 25% to \\\u003C 80% of predicted normal at Visit 2.\n* Documented history of ≥ 2 moderate or ≥ 1 severe COPD exacerbations in the 12 months prior to screening.\n* Documented stable regimen of inhaled triple maintenance therapy or inhaled dual maintenance therapy for ≥ 3 months prior to screening.\n* CAT score ≥ 10 at Visit 1.\n* Current or ex-smokers with a cigarette smoking history of ≥ 10 pack-years.\n* Participants who are clinically stable and free from an exacerbation of COPD for 4 weeks prior to Visit 1 and are also exacerbation free for at least 4 weeks (28 days) prior to Visit 3 (randomisation).\n* Negative pregnancy test at Visit 1 and Visit 3 for Women Of Child-Bearing Potential (WOCBP).\n\nExclusion Criteria:\n\n* Clinically important pulmonary disease other than COPD (eg, asthma \\[current diagnosis per GINA or other accepted guidelines\\], active pulmonary infection, clinically significant bronchiectasis when bronchiectasis is the predominant diagnosis, pulmonary fibrosis, cystic fibrosis, hypoventilation syndrome associated with obesity, lung cancer, alpha-1 antitrypsin deficiency or primary ciliary dyskinesia).\n* Radiological findings suggestive of a respiratory disease other than COPD that is significantly contributing to the participant's respiratory symptoms.\n* Any unstable disorder, including, but not limited to, CV, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric disorder, major physical and\u002For cognitive impairment.\n* Significant left heart failure.\n* Unstable angina, acute coronary syndrome\u002Facute myocardial infarction or coronary intervention with percutaneous coronary intervention\u002Fcoronary artery bypass graft within 6 months of randomisation, uncontrolled arrhythmia, or cardiomyopathy, clinically significant aortic stenosis, or signs of pulmonary oedema or volume overload.\n* Pulmonary arterial hypertension, either idiopathic or due to connective tissue or thromboembolic disease.\n* History of another underlying condition that predisposes the participant to infections.\n* History of ulcerative colitis, Crohn's disease, or microscopic colitis diagnosed by either a gastroenterologist or by histopathology.\n* Abnormal laboratory findings.\n* Participants with evidence of active liver disease and\u002For evidence of chronic liver disease.\n* Participants with history of HIV infection or who test positive for HIV.\n* History of lung volume reduction surgery.\n* Current or history of malignancy within 5 years before the screening visit.",{"count":110,"type":22},987,[60],"This Phase IIb dose-ranging study will evaluate the efficacy and safety of 2 different doses of AZD6793 compared with placebo tablets in participants with moderate to very severe chronic obstructive pulmonary disease.",[27],[90,115,116,117,118,119,120],"Moderate COPD","Severe COPD","Very Severe COPD","chronic obstructive pulmonary disease","AZD6793","IRAK4 Inhibitor",{"date":122,"type":37},"2026-08-11",{"date":124,"type":37},"2025-06-27",{"date":126,"type":22},"2027-11-05",{"name":128,"class":73},"AstraZeneca",368,{"id":131,"slug":132,"hasResults":12,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":12,"sex":18,"minAge":138,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":57,"phases":142,"briefSummary":143,"conditions":144,"keywords":145,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":45},"100650555","time-course-of-respiratory-oscillometry-parameters-during-nasal-high-flow-therapy-in-stable-chronic-obstructive-pulmonary-disease-100650555","NCT07750613","Time Course of Respiratory Oscillometry Parameters During Nasal High-Flow Therapy in Stable Chronic Obstructive Pulmonary Disease","Time Course of Respiratory Oscillometry Parameters During Exposure to Nasal High-Flow Therapy in People With Stable Chronic Obstructive Pulmonary Disease: A Prospective Open-Label Single-Arm Physiological Study","NHFlOscillo","Inclusion Criteria:\n\n* Age \\>18 years and \\\u003C85 years;\n* Chronic obstructive pulmonary disease classified as Global Initiative for Chronic Obstructive Lung Disease (GOLD) spirometric grade III or IV;\n* Modified Medical Research Council dyspnea score ≥2;\n* Completed a pulmonary rehabilitation program at the study center;\n* Clinically stable, defined as no exacerbation and no treatment change during the previous 4 weeks;\n* With or without long-term oxygen therapy;\n* Never previously used nasal high-flow therapy;\n* Affiliated with a French social security system;\n* Able to read and understand the participant information and provide written informed consent.\n\nNon-inclusion Criteria:\n\n* Under legal guardianship or curatorship;\n* Confirmed or suspected pregnancy;\n* Unable to provide informed consent;\n* Primary diagnosis of another chronic obstructive respiratory disease, such as asthma or primary bronchiectasis;\n* Severe or unstable cardiovascular disease, including uncontrolled cardiac arrhythmia, severe heart failure, recent myocardial infarction, or unstable angina;\n* Hemodynamic instability.\n\nExclusion Criteria:\n\n• None","18 Years","85 Years",{"count":141,"type":22},20,[85],"Chronic obstructive pulmonary disease (COPD) can affect the small airways and alter respiratory mechanics. Nasal high-flow therapy delivers warmed and humidified gas through nasal cannulas and may change airway resistance. Respiratory oscillometry is a noninvasive test that measures respiratory resistance and reactance during quiet breathing.\n\nThis prospective, single-center study will enroll 20 adults with severe or very severe stable COPD who have never used nasal high-flow therapy. During a single study visit lasting approximately 6 hours, participants will receive individualized nasal high-flow therapy for 4 hours. Respiratory oscillometry will be measured before exposure, immediately after device titration, and after 30, 60, 120, 180, and 240 minutes.\n\nThe primary objective is to describe the time course of the difference between respiratory resistance measured at 5 hertz and at 20 hertz (R5-R20), an indirect index of peripheral airway mechanical abnormalities. Secondary objectives are to describe changes in total and proximal respiratory resistance, respiratory reactance, resonant frequency, and area of reactance. The hypothesis is that nasal high-flow exposure will produce measurable, time-dependent changes in respiratory oscillometry parameters.",[27],[146,147,148,149,150,151],"Nasal high-flow therapy","High-flow nasal cannula","Respiratory oscillometry","Impulse oscillometry","Small airways","Respiratory mechanics","2026-08-06",{"date":92,"type":37},{"date":155,"type":22},"2026-09-01",{"date":157,"type":22},"2028-02-29",{"name":159,"class":44},"ADIR Association",{"id":161,"slug":162,"hasResults":12,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":12,"sex":18,"minAge":138,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":170,"conditions":171,"keywords":173,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":178,"startDateStruct":179,"completionDateStruct":180,"leadSponsor":182,"locationsCount":45},"100650444","factors-associated-with-acceptance-of-home-based-pulmonary-telerehabilitation-in-copd-100650444","NCT07747571","Factors Associated With Acceptance of Home-Based Pulmonary Telerehabilitation in COPD","Factors Associated With Acceptance or Refusal of Participation in a Home-Based Pulmonary Telerehabilitation Program Among Adults With Chronic Obstructive Pulmonary Disease: A Retrospective Study","ACCEPT-TR","Inclusion Criteria:\n\n* Adults with COPD who were screened at ADIR Association between May 2024 and April 2025 for an 8-week home-based pulmonary telerehabilitation feasibility study. Please refer to ClinicalTrials.gov identifier NCT05314686.\n\nExclusion Criteria:\n\n* Not applicable",{"count":169,"type":22},50,"Pulmonary rehabilitation improves symptoms, exercise capacity, and quality of life in people with chronic obstructive pulmonary disease (COPD), but access and participation may be limited by travel, organizational, logistical, and personal barriers. Home-based pulmonary telerehabilitation may reduce some of these barriers, although not all eligible individuals accept this mode of care. Identifying the characteristics associated with acceptance or refusal of this model is therefore essential to better define the population most likely to benefit from this approach, tailor the program's delivery and content, and identify potential remaining barriers in order to improve access to care.\n\nThis retrospective study will use existing data from adults with COPD who were screened at ADIR Association between May 2024 and April 2025 for an 8-week home-based pulmonary telerehabilitation feasibility study. Of 50 potentially eligible individuals, 21 accepted participation and 29 declined. Demographic, clinical, functional, psychological, and geographic characteristics will be compared between individuals who accepted and those who declined participation. Documented reasons for refusal will be described, and factors associated with refusal will be explored using logistic regression.",[27,172],"Pulmonary Rehabilitation",[174,175,176,177],"Telerehabilitation","Home-based pulmonary rehabilitation","Patient preference","Access to care",{"date":92,"type":37},{"date":155,"type":22},{"date":181,"type":22},"2026-10-31",{"name":159,"class":44},{"id":184,"slug":185,"hasResults":12,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":139,"enrollmentInfo":191,"targetDuration":4,"studyType":57,"phases":193,"briefSummary":194,"conditions":195,"keywords":196,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":141},"100646841","phase-2-to-evaluate-the-effect-of-expd-101fxs7553-compared-with-placebo-in-patients-with-copd-over-52-weeks-of-treatment-100646841","NCT07684820","To Evaluate the Effect of EXPD-101\u002FFXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment","A Randomized, Double-Blind, Placebo-controlled, Parallel Arm, 52-week Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Two Doses of EXPD-101 in Participants With COPD","Navigator","Inclusion Criteria:\n\n1. Provided written informed consent for the study\n2. Body mass index (BMI) ≥ 18.5 kg\u002Fm2 and \\\u003C 35 kg\u002Fm2 at screening (weight ≥ 50 kg for males and ≥ 45 kg for females)\n3. Diagnosis of COPD for at least 1 year\n4. COPD with physician-confirmed diagnosis of chronic bronchitis (persistent, productive cough and sputum for at least 3 months in the past year)\n5. At least 2 moderate or \\> 1 severe exacerbation within 12 months prior to screening\n6. Current or ex-tobacco smokers with history of ≥ 10 pack-years (1 pack year = 20 cigarettes smoked per day for 1 year);\n7. Stable maintenance therapy with either dual or triple inhaled therapy for ≥ 3 months prior to enrollment per below:\n\n   1. Dual therapy: long-acting beta-2 agonist\u002Fmuscarinic antagonist (LABA\u002FLAMA) or inhaled corticosteroids (ICS)\u002FLAMA, or ICS\u002FLABA OR\n   2. Triple therapy: ICS\u002FLAMA\u002FLABA\n8. Post-BD FEV1\u002FFVC \\\u003C 0.7 and post-BD FEV1(% predicted) ≥ 40% at Screening\n9. COPD Assessment Test (CAT) score ≥ 10 at Screening\n10. If participant is of childbearing potential, must commit to practicing highly effective methods of birth control and not donating eggs during the study and at least 14 days after the last dose.\n11. Male participants commit to the following during the study and for at least 14 days after the last dose:\n\n    1. Practice true sexual abstinence (refrain from heterosexual intercourse)\n    2. Use a condom with any female partner of childbearing potential and ensure that the partner uses a highly effective contraceptive method (eg, IUD\u002FIUS, combined hormonal contraception, progestogen-only contraception, or bilateral tubal occlusion).\n    3. Be vasectomized (≥ 3 months prior to screening)\n    4. Refrain from donating sperm during the Treatment Period and for at least 14 days after the last dose of the IP\n\nExclusion Criteria:\n\n1. COPD exacerbation within the 4 weeks prior to randomization.\n2. Clinically important pulmonary disease other than COPD (eg, asthma, active lung infection, clinically significant bronchiectasis, pulmonary fibrosis, cystic fibrosis, lung cancer, alpha-1 antitrypsin deficiency, tuberculosis).\n3. Significant immunodeficiency and\u002For positive serological tests for hepatitis B, hepatitis C, or known human immunodeficiency virus (HIV) infection.\n4. Pneumonia requiring antibiotics or antiviral medication within 28 days prior to Visit 1.\n5. History of clinically significant infection (excluding pneumonia), acute upper or lower respiratory infection, requiring antibiotics or antiviral medication within 14 days prior to Visit 1.\n6. Evidence of active liver disease (with or without ongoing treatment)\n7. Participants with a QT interval, from the ECG conducted at Screening Visit 1, corrected with Fridericia's formula (QTcF) \\> 450 msec (or QTcF \\> 480 msec in participants with bundle branch block).\n8. Current or history, within the past year of Visit 1, of substance and\u002For alcohol abuse.\n9. History of cancer except:\n\n   1. Participants who have had basal cell carcinoma, localized squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible to participate in the study provided that curative therapy was completed at least 12 months prior to Visit 1\n   2. Participants who have had other malignancies are eligible provided that curative therapy was completed at least 5 years prior to Visit 1\n10. Any clinically significant abnormal findings in physical examination, vital signs, hematology, clinical chemistry, or urinalysis during Screening Period, which in the opinion of the investigator, may put the participant at risk because of his\u002Fher participation in the study, or may influence the results of the study, or the participant's ability to complete the entire duration of the study.\n11. Known history of allergy or reaction to any component of the investigational product formulation\n12. Current treatment with biologic drugs for COPD (eg, dupilumab, mepolizumab) or use of Therapeutics, biologics within 5 half-lives or 4 months, whichever is longer, from randomization\n13. Current long-term treatment with oxygen therapy \\> 12 hours per day\n14. Use of immunoglobulin or blood products in 30 days prior to Screening\n15. Received a live attenuated vaccine within 30 days prior to Screening\n16. Participants who are participating in the acute phase of a pulmonary rehabilitation program, i.e. who started rehabilitation \\\u003C 4 weeks prior to screening (Note: participants in the maintenance phase of a rehabilitation program can be included).\n17. History or active conditions associated with the onset of non-hereditary palmoplantar keratosis:\n18. Have any tooth that can potentially cause pain or infection as noted in the oral exam unless they are corrected before the study\n19. Has active periodontal disease and are either:\n\n    1. Currently treated by a dentist for this condition or\n    2. Expected to have periodontal disease-related procedures within the study period\n20. Are scheduled to have tooth extraction that will occur during the study period",{"count":192,"type":22},600,[60],"This is a Phase 2 study of the efficacy, safety, tolerability and pharmacokinetics of two doses of EXPD-101 in participants with COPD. Study participants will be randomized to receive either study drug or placebo administered once daily for 52 weeks.",[27],[197,90,198,199,200,201,202],"Chronic Obstructive Pulmonary Disease","Bronchitis","DPP","DPP1","DPP Inhibitor","DPP1 Inhibitor",{"date":204,"type":37},"2026-08-07",{"date":206,"type":37},"2026-06-30",{"date":208,"type":22},"2028-07-11",{"name":210,"class":73},"Expedition Therapeutics, Inc",{"id":212,"slug":213,"hasResults":12,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":217,"eligibilityCriteria":218,"healthyVolunteers":12,"sex":18,"minAge":219,"maxAge":220,"enrollmentInfo":221,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":223,"conditions":224,"keywords":231,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":45},"100650590","improving-patient-centered-care-for-underserved-older-african-american-patients-with-cardiovascular-comorbidities-100650590","NCT07748858","Improving Patient-Centered Care for Underserved Older African American Patients With Cardiovascular Comorbidities","Improving Patient-Centered Care for Underserved Older African American Patients With Cardiovascular Comorbidities: A Pilot Study of the Patient Priorities Care Approach at Cooper Green Mercy Health Services Authority (PPC-HEART)","PPC Heart","Inclusion Criteria:\n\n* greater than or equal to 50 years old\n* at least one CVD (i.e., coronary artery disease, hypertension, heart failure, arrhythmias, cardiomyopathy, peripheral artery disease, stroke, and valvular heart disease)\n* at least one coexisting chronic condition (i.e., inflammatory joint disease, COPD\u002Fasthma, diabetes, chronic kidney disease, and cancer one-year post-treatment)\n* a caregiver of a participant, or a provider who serves this population.\n\nExclusion Criteria:\n\n* Axis I psychiatric (schizophrenia, bipolar disorder), dementia, suicidal ideation,\n* active substance use disorder nursing home or assisted living facility residence.","50 Years","99 Years",{"count":222,"type":22},29,"This is formative evaluation trial guided by the Values Clarification Theory25 and the Cultural Values Theory26, with specific aims to: Aim 1. Develop a culturally appropriate version of the PPC Approach for older AAs with CVCs by assembling a community advisory group of 3 primary care clinicians, 3 older AA patients with CVCs, and 3 AA persons who care for AA patients with CVCs to solicit feedback on the PPC Approach. Aim 2. Determine the acceptability (e.g., program appraisal interviews) and feasibility (e.g., avg. length of program sessions, program participation rate, study completion rate) of the PPC Approach among a sample 20 of under-resourced older southern AA patients with CVCs receiving primary care at Cooper Green Mercy Health Services Authority. Aim 3. Examine the ability of participants to complete pre- and post-test (8 weeks post-baseline) measures of perception of care, treatment burden, shared decision-making, and patient-clinician communication exchange.",[225,226,227,228,229,27,230],"Cardiovascular","Comorbidity","Diabetes","Inflammatory Joint Diseases","Chronic Kidney Diease","Cardiovascular Disease",[232,233,197,234,235,236,237,238],"Cardiovascular Diseases","Chronic Kidney Disease","Patient-Centered Care","Shared Decision Making","Care Coordination","Older Adults","Multiple Chronic Conditions","2026-07-31",{"date":152,"type":37},{"date":242,"type":37},"2026-05-01",{"date":244,"type":22},"2027-06",{"name":246,"class":44},"University of Alabama at Birmingham",{"id":248,"slug":249,"hasResults":12,"nctId":250,"briefTitle":251,"officialTitle":251,"acronym":252,"eligibilityCriteria":253,"healthyVolunteers":12,"sex":18,"minAge":138,"maxAge":4,"enrollmentInfo":254,"targetDuration":4,"studyType":57,"phases":256,"briefSummary":257,"conditions":258,"keywords":264,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":74},"100649602","primary-palliative-care---a-feasibility-cluster-trial-100649602","NCT07737899","Primary Palliative Care - a Feasibility Cluster Trial","PrimPal","Inclusion Criteria:\n\n* Aged 18 years or older.\n* Enrolled as a patient on the list of a recruited General Practitioner in one of the participating Family Health Units.\n* Diagnosed with one or more of the following advanced chronic conditions:\n* Advanced-stage neoplasm (metastatic\u002Fstage IV cancer);\n* Chronic Obstructive Pulmonary Disease (COPD) - GOLD classification III or IV;\n* Congestive Heart Failure (CHF) - New York Heart Association (NYHA) functional classification III or IV;\n* Chronic Kidney Disease (CKD) - stage IV or V.\n\nExclusion Criteria:\n\n* Refusal to provide informed consent or to participate in the study at any point.\n* Disease severity requiring urgent medical intervention (acute crisis\u002Femergency care need at time of recruitment).",{"count":255,"type":22},30,[85],"This feasibility cluster-controlled randomized trial (RCT) evaluates a complex intervention for the delivery of primary palliative care in Family Health Units (FHUs). The intervention consists of training General Practitioners (GPs) in palliative care through a 30 hour e-learning program and implementing a structured consultation model (4 consultations over 12 weeks) for adult patients with advanced chronic illness. One FHU will receive the intervention and one FHU will follow usual care. The primary goal is to assess feasibility metrics (GP adherence, patient recruitment rate, and patient retention rate), which will inform the design of a subsequent full-scale cluster RCT.",[259,260,261,27,262,263],"Palliative Care","Primary Palliative Care","Advanced Cancer","Congestive Heart Failure Chronic","Chronic Kidney Disease (Stages 4 and 5)",[265,260,266,267,268,269,270,271],"Palliative care","General practice","Family medicine","Feasibility study","Cluster randomized controlled trial","Complex intervention","Chronic disease",{"date":273,"type":37},"2026-08-03",{"date":275,"type":22},"2026-10-01",{"date":277,"type":22},"2027-08-31",{"name":279,"class":44},"University of Coimbra",{"id":281,"slug":282,"hasResults":12,"nctId":283,"briefTitle":284,"officialTitle":284,"acronym":285,"eligibilityCriteria":286,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":287,"targetDuration":4,"studyType":57,"phases":289,"briefSummary":291,"conditions":292,"keywords":293,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":306},"100545061","phase-3-multi-center-clean-air-randomized-controlled-trial-in-copd-100545061","NCT06376994","Multi-Center Clean Air Randomized Controlled Trial in COPD","Clean Air","Inclusion criteria\n\nTo be eligible, subjects must meet all these criteria:\n\n1. Age ≥ 40 years.\n2. Self-report of physician diagnosis of COPD.\n3. Spirometry confirmed airway obstruction (post-bronchodilator spirometry of forced expiratory volume in 1 second (FEV1)\u002Fforced vital capacity (FVC) \\\u003C 0.7) as defined by the Global Initiative for Obstructive Lung Disease (GOLD) criteria (6, 11)\n4. Tobacco exposure ≥ 10 pack-years. This refers to regular cigarette tobacco consumption.\n5. Self-reported former smoker of at least 6 months' duration. This does not include e-cigarette use.\n6. COPD Assessment Test (CAT) score ≥ 10, Modified Medical Research Council dyspnea scale (mMRC) ≥ 2, or history of moderate or severe exacerbation in the past 12 months (as defined by history of receiving a course of systemic corticosteroids or antibiotics for respiratory problems; or visiting an emergency department or being hospitalized for a COPD exacerbation within the past 12 months.)\n\nExclusion criteria\n\nTo be eligible, subjects must not meet any one of these criteria:\n\n1. Living in a location other than home (e.g., long-term care facility, nursing home)\n2. Other chronic lung diseases, except asthma\n3. Condition with less than a year of life expectancy (e.g., metastatic cancer) or in hospice\n4. Spends \\>2 months per year in location other than home; or plans to change residence in the next 12 months\n5. Pregnant or breastfeeding\n6. Current air cleaner use in the home (\\*If the individual is willing to discontinue use of the personal air cleaner, this person can be eligible if all other eligibility has been met)\n7. Inability to bring air cleaners (about 15 pounds each) into home, either by self, friend, or relative\n8. Deemed by the study investigator to be unable to complete study protocol, including likely lack of internet connectivity\n9. Participating in another interventional clinical trial",{"count":288,"type":22},770,[290],"PHASE3","This is a multi-center randomized, sham-controlled clinical trial to determine the effectiveness of an air cleaner intervention aimed at improving indoor air quality on reducing COPD exacerbation risk and improving quality of life, functional status, rescue medication use.",[27],[294,295,296,297],"air cleaner","indoor air quality","quality of life","rescue medication use","2026-07-30",{"date":239,"type":37},{"date":301,"type":37},"2024-05-24",{"date":303,"type":22},"2029-08-31",{"name":305,"class":44},"JHSPH Center for Clinical Trials",11,{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":313,"eligibilityCriteria":314,"healthyVolunteers":17,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":315,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":317,"conditions":318,"keywords":332,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":351},"100650085","health-for-hungary-h4h---longitudinal-collection-of-blood-samples-and-corresponding-data-100650085","NCT07743021","Health for Hungary (H4H) - Longitudinal Collection of Blood Samples and Corresponding Data","Health for Hungary - Longitudinal Collection of Blood Samples and Corresponding Data for Longterm Evaluation of Innovative Diagnostic Techniques in Subjects Without Clinically Relevant Disorders at Baseline to Institute Molecular Fingerprinting Reference Norms","H4H","Low- and Moderate-risk Cohort:\n\nInclusion Criteria:\n\n1. Signed informed consent form (ICF) of the study.\n2. Age \\> 40 years.\n3. Willingness to fill in the study questionnaire.\n4. No clinically relevant symptoms as assessed by the investigator, subjects with existing medical conditions may be eligible given that they are symptom free and that full treatment of the condition is medically confirmed.\n5. Willingness to participate in future visits.\n\nExclusion Criteria:\n\n1. Self-reported pregnancy (no test).\n2. Indications of clinically relevant medical conditions in self-reported healthy subjects.\n3. Self-reported symptom-free HIV, HCV and HBV infections. If HIV, HBV or HCV serology test is done and any of them are positive, the subject will be considered a screen failure.\n4. Any conditions preventing blood-draw.\n5. Vulnerable subjects.\n6. Foreseeable lack of compliance.\n7. Participation in another sample collection project of the same sponsor, in order to avoid double evaluation of the same subject.\n8. Participation (currently or in the past month) in an early phase clinical trial (phases I and II) involving testing of pharmaceutical products, if the last dose of pharmaceutical product administration was within 30 days of the first sample collection, and \u002F or further pharmaceutical product administration is planned.\n9. Vaccination within the last 14 days.\n\nHigh-risk Cohort:\n\nInclusion Criteria:\n\n1. Signed informed consent form (ICF) of the study.\n2. Age \\> 50 years.\n3. Willingness to fill in the study questionnaire.\n4. Willingness to participate in future visits and medical investigations, the presence of at least 2 of the following 3 risk factors (inclusion criteria #5-7):\n5. Hypertension, receiving antihypertensive treatment.\n6. Dyslipidemia\u002F Hypercholesterolemia (\\>5.2mmol\u002FL total cholesterol level), on or not on statin-treatment.\n7. Active or former smoker, with smoking history of at least 20 pack-years, and\u002For the presence of intermediate lung nodule on prior LDCT testing.\n8. No clinically relevant symptoms as assessed by the investigator; subjects with existing medical conditions may be eligible given that they are symptom free and that treatment of the condition is well documented.\n\nExclusion Criteria:\n\n1. Self-reported pregnancy (no test).\n2. Cardiovascular disease (including obstructive coronary artery disease, peripheral artery disease, aortic aneurysm) or other clinically significant heart disease (congenital, valvular heart disease, cardiomyopathy, heart failure and heart disease requiring ICD \\[implantable cardioverter defibrillator\\] or pacemaker therapy).\n3. Interstitial lung disease or severe COPD (chronic obstructive pulmonary disease) in GOLD stages 3 or 4.\n4. Active cancer or malignant disease with less than 5 years history of remission.\n5. Indications of clinically relevant medical conditions in self-reported healthy subjects, especially if (a) the condition requires regular or constant specialist checkups, or (b) pharmacological therapy indicates the presence of significant NCDs or multimorbidity, i.e., chronic polypharmacy (use of 5 or more medications at enrollment or over the last 6 months), or drug therapy necessitating a specialist input for initiation or management (e.g., combined anti-diabetic treatment with two or more medications).\n6. Self-reported symptom-free HIV, HCV and HBV infections. If HIV, HBV or HCV serology test is done and any of them are positive, the subject will be considered a screen failure.\n7. Any conditions preventing blood-draw or CT scans.\n8. Vulnerable subjects.\n9. Foreseeable lack of compliance.\n10. Participation in another sample collection project of the same sponsor, in order to avoid double evaluation of the same subject. 'High-risk' subjects enrolled in the low- and moderate-risk arm of the H4H study might be reallocated to the high-risk study arm after the first 4-5 visits.\n11. Participation (currently or in the past month) in an early phase clinical trial (phases I and II) involving testing of pharmaceutical products, if the last dose of pharmaceutical product administration was within 30 days of the first sample collection, and\u002For further pharmaceutical product administration is planned.\n12. Vaccination within the last 14 days of sample collection.",{"count":316,"type":22},15000,"The Health for Hungary (H4H) study collects blood samples and corresponding health data to investigate healthy aging and health-to-disease transitions in middle-aged and elderly participants.\n\nIndications Studied:\n\nApparently healthy, symptom-free participants are enrolled and followed up to study the onset of new-onset diseases with special emphasis on non-communicable diseases (NCDs).\n\nStudy Design:\n\nSingle-country, multicenter, prospective, longitudinal survey.\n\nObjectives:\n\nThe study aims to establish reference ranges of blood parameters using routine clinical blood tests and high-information-content methods, including proteomics, metabolomics and the so-called infrared molecular fingerprinting.\n\nThe study also aims to identify novel biomarkers of major non-communicable diseases, including atherosclerotic cardiovascular disease, cancer, diabetes and chronic respiratory disease.",[319,320,321,322,323,324,325,326,327,328,329,330,331,27],"Non-communicable Diseases (NCD)","Neoplams","Cancer","Lung Cancer (NSCLC)","Cardiovascular Diseases (CVD)","Atherosclerotic Cardiovascular Disease (ASCVD)","Peripheral Artery Disease (PAD)","Coronary Artery Disease (CAD)","Stroke (CVA) or TIA","Diabetes Mellitus (DM)","Type 2 Diabetes (T2DM)","Prediabetes","Chronic Respiratory Diseases",[333,334,335,336,337,338,339,340,341,342],"Personalized health","Molecular fingerprints","Longitudinal health monitoring","Early-stage disease detection","Innovative research platforms","Precision care","Proteomics","Metabolomics","in vitro diagnostics","Prevention medicine","2026-07-29",{"date":273,"type":37},{"date":346,"type":37},"2021-07-27",{"date":348,"type":22},"2030-12-31",{"name":350,"class":44},"Center for Molecular Fingerprinting Research Nonprofit LLC",33,{"id":353,"slug":354,"hasResults":12,"nctId":355,"briefTitle":356,"officialTitle":357,"acronym":358,"eligibilityCriteria":359,"healthyVolunteers":12,"sex":18,"minAge":219,"maxAge":139,"enrollmentInfo":360,"targetDuration":4,"studyType":57,"phases":362,"briefSummary":364,"conditions":365,"keywords":366,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":370,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":45},"100607704","phase-4-129-xe-mri-study-of-single-triple-therapy-inhaler-effects-in-copd-patients-with-moderate-severe-dyspnea-andor-poor-health-status-with-high-or-low-risk-of-exacerbation-100607704","NCT07192016","129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and\u002For Poor Health Status With High or Low Risk of Exacerbation","Mechanistic 129-Xe MRI Study of Single Inhaler FF\u002FUMEC\u002FVI Effects in COPD Patients With Persistent, Moderate-severe Dyspnea and\u002For Poor Health Status With High or Low Risk of Exacerbation","MUST","Inclusion Criteria:\n\n* patient understands study procedures and is willing to participate in the study as indicated by the patient's signature\n* provision of written, informed consent prior to any study specific procedures\n* males and females 50-85 years of age\n* stable COPD, currently on dual therapy LAMA\u002FLABA or ICS\u002FLABA or initial maintenance therapy for at least 3 months\n* mMRC score ≥2 and\u002For CAT score ≥10\n* Low risk subgroup: participant has experienced ≤1 exacerbation in the past year and no hospitalizations for COPD High risk subgroup: participant has experienced ≥2 exacerbations in the past year\n* Female of childbearing potential (after menarche) must ensure that they are using an effective form of birth control for at least 2 months prior to each imaging visit. Examples of effective birth control include:\n\n  1. True sexual abstinence\n  2. A vasectomized sexual partner\n  3. Implanon®\n  4. Female sterilization by tubal occlusion\n  5. Effective intrauterine device (IUD)\u002Flevonogestrel intrauterine system (IUS)\n  6. Depo-Provera™ injections\n  7. Oral contraceptive\n  8. Evra Patch™\n  9. Nuvaring™\n* Female permanently sterile due to: 1) documented hysterectomy, 2) documented bilateral salpingectomy, and 3) documented bilateral oophorectomy\n* Postmenopausal female: defined as female with no menses for 12 months without an alternative medical cause\n* Females of childbearing potential (after menarche) must agree to use a highly effective form of birth control, as defined above, from enrollment, throughout the study duration, and 8 weeks after last dose of study drug, with negative urine pregnancy test taken within 24 hr of any planned CT examination at Visit-1 through Visit 3\n* Male participants who are sexually active with a woman who can still have children, must agree to use a double barrier method of contraception (male condom with diaphragm or male condom with cervical cap) from the first dose of the study drug until 8 weeks after last dose\n\nExclusion Criteria:\n\n* Patient has an implanted mechanically, electrically, or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical staples (including clips or metallic sutures and\u002For ear implants) (at the discretion of the MRI Technologist)\n* In the investigator's opinion, participant suffers from any physical, psychological or other condition(s) that might prevent performance of the MRI or CT, such as severe claustrophobia\n* Participants who are pregnant, breastfeeding or have a positive pregnancy test at initial screening visit\n* Participant is unable to perform spirometry or plethysmography maneuvers\n* Participant is unable to perform MRI and CT breath-hold maneuvers\n* Participant has an unstable cardiovascular, gastro-intestinal, hepatic, renal, neurologic, metabolic or psychiatric disease\n* Participation in any clinical trial of an investigational agent or procedure within three months prior to screening or during the study\n* Known history of allergy or reaction to the study drug formulation\n* Participant has a blood pressure of \\>150 mmHg systolic or \\>95 mmHg diastolic on more than 2 measurements done \\>5 minutes apart at Visit-1\n* Participants with a recently (\\\u003C2 months) documented diagnosis of asthma",{"count":361,"type":22},60,[363],"PHASE4","The goal of this study is to study how 12-weeks daily (and optional 48-weeks) single inhaler triple therapy (fluticasone furoate (FF)-an inhaled corticosteroid; umeclidinium (UMEC)-a long-acting muscarinic antagonist; vilanterol (VI)-a long-acting β2-adrenergic agonist) works to treat adults with COPD. The investigators will compare the effects of this medication on adults with COPD who are at low risk of a flare-up and adults with COPD who are at high risk of a flare-up. The main questions it aims to answer are:\n\n* Does FF\u002FUMEC\u002FVI improve ventilation defect percent as measured on 129-Xenon MRI in adults with moderate-severe COPD\n* Evaluate the relationships between the ventilation defect percent and lung function test results\n\nParticipants will:\n\n* Take the inhaler FF\u002FUMEC\u002FVI once daily for 12-weeks (optional 48-weeks)\n* visit Robarts 2 times (with optional 3rd visit) for tests and imaging",[27],[367,90,368,369],"Pulmonary Function","129-Xenon","Magnetic Resonance Imaging",{"date":239,"type":37},{"date":372,"type":37},"2026-04-24",{"date":374,"type":22},"2027-10",{"name":376,"class":44},"Western University, Canada",{"id":378,"slug":379,"hasResults":12,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":4,"eligibilityCriteria":383,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":384,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":385,"conditions":386,"keywords":389,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":399,"locationsCount":4},"100649483","prevalence-and-clinical-outcome-of-eosinophilic-copd-100649483","NCT07734883","Prevalence and Clinical Outcome of Eosinophilic COPD","Prevalence and Clinical Outcome of Eosinophilic COPD at Assiut University","Inclusion Criteria:\n\n* Patients aged \\> 40 years.\n* Confirmed diagnosis of COPD according to GOLD 2026 guidelines.\n* Presented with acute exacerbation of COPD (AECOPD) characterized by the onset or worsening of at least two symptoms (cough, phlegm, purulent sputum, wheezing, or dyspnea) persisting for a minimum of 48 hours, excluding other potential causes, such as left or right cardiac dysfunction, pulmonary embolism, pneumothorax, pleural effusion, arrhythmia and other related diseases.\n\nExclusion Criteria:\n\n* Patients with asthma or asthma-COPD overlap.\n* Patients who need ICU admission.\n* Patients receiving systemic corticosteroids within the previous 4 weeks.\n* Hematological disorders affecting eosinophil count.\n* Active pulmonary tuberculosis.\n* Parasitic infections confirmed by stool analysis.",{"count":83,"type":22},"Chronic Obstructive Pulmonary Disease (COPD) is a lung condition characterized by chronic breathing symptoms and progressive airflow blockages. A specific type of COPD, known as eosinophilic COPD, involves higher levels of white blood cells called eosinophils and is known to influence disease outcomes and treatment responses. Currently, there is limited data regarding the prevalence and clinical outcomes of eosinophilic COPD in Upper Egypt, particularly among patients at Assiut University Hospitals.\n\nThe main objective of this prospective observational study is to determine how common eosinophilic COPD is among patients experiencing an acute worsening of their COPD symptoms (an exacerbation) at Assiut University Hospitals. The study also aims to evaluate the clinical outcomes associated with this specific phenotype.\n\nResearchers will observe patients over the age of 40 with a confirmed COPD diagnosis who are admitted to the hospital for an acute exacerbation. As part of their standard hospital care, participants will undergo routine clinical assessments, including a review of their medical history, physical examinations, lung function tests (spirometry), and standard blood tests to measure their blood eosinophil count.\n\nThe study will compare patients with eosinophilic COPD to those with non-eosinophilic COPD. Researchers will specifically evaluate differences in the severity of the exacerbation, the duration of the hospital stay, and the need for ventilator support. The findings aim to contribute to better, more personalized treatment strategies and improved clinical outcomes for COPD patients in the region.",[27,387,388],"Eosinophilic COPD","Acute Exacerbation of Chronic Obstructive Pulmonary Disease",[387,390,391,392],"COPD Exacerbation","Blood Eosinophils","Sputum Eosinophilia","2026-07-25",{"date":343,"type":37},{"date":396,"type":22},"2026-08",{"date":398,"type":22},"2027-09",{"name":400,"class":44},"Assiut University",{"id":402,"slug":403,"hasResults":12,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":4,"eligibilityCriteria":407,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":54,"enrollmentInfo":408,"targetDuration":4,"studyType":57,"phases":410,"briefSummary":411,"conditions":412,"keywords":413,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":4},"100649208","phase-2-pra-216-copd-safety-and-biomarker-study-100649208","NCT07730281","PRA-216 COPD Safety and Biomarker Study","A Phase 2 Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Safety and Efficacy of PRA-216 in Participants With Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation","Inclusion Criteria:\n\n* Age 40-80\n* Willing and able to attend all study visits, comply with study requirements.\n* Able and willing to provide written informed consent\n* Documented COPD diagnosis prior for at least 12 months prior to screening.\n* Currently receiving maintenance COPD medications at a stable dose for at least 2 months prior to visit 1\n\nExclusion Criteria:\n\n* Evidence of clinically significant pulmonary condition or disease other than COPD\n* Any physical or psychological condition that prohibits study completion\n* Known history of illicit drug use or drug abuse, harmful alcohol use (at the Investigator's discretion), alcoholism within 12 months prior to the first dose of study agent\n* History of severe allergic reactions or hypersensitivity\n* Receipt of immunosuppressant therapies for asthma within 3 months of screening\n* Major surgery occurring within 8 weeks months prior to first dose of investigational product.\n* Use of any marketed or investigational monoclonal or polyclonal antibody therapy within 4 months or 5 half-lives prior to visit 1.",{"count":409,"type":22},40,[60],"This study will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to placebo in patients with chronic obstructive pulmonary disease (COPD).",[27],[414,415,416],"Inflammatory response","pharmacokinetics","pharmacodynamics","2026-07-23",{"date":419,"type":37},"2026-07-28",{"date":421,"type":22},"2026-08-01",{"date":423,"type":22},"2027-09-01",{"name":425,"class":73},"Prana Therapies Inc",{"id":427,"slug":428,"hasResults":12,"nctId":429,"briefTitle":430,"officialTitle":430,"acronym":431,"eligibilityCriteria":432,"healthyVolunteers":12,"sex":18,"minAge":138,"maxAge":4,"enrollmentInfo":433,"targetDuration":4,"studyType":57,"phases":435,"briefSummary":436,"conditions":437,"keywords":439,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":443,"completionDateStruct":444,"leadSponsor":446,"locationsCount":4},"100648580","new-diagnostic-approaches-in-the-management-of-inflammatory-lung-diseases-100648580","NCT07723638","New Diagnostic Approaches in the Management of Inflammatory Lung Diseases","ALPI","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Diagnosis of chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), or combined pulmonary fibrosis and emphysema (CPFE), established according to current international diagnostic guidelines.\n* Ability and willingness to provide written informed consent.\n* Willingness to provide blood and saliva samples for biomarker analyses.\n* Willingness and ability to undergo clinical assessments and scheduled follow-up visits.\n* Willingness and ability to use study monitoring devices, including environmental monitoring devices and, where applicable, telemedicine tools.\n\nExclusion Criteria:\n\n* Age younger than 18 years.\n* Inability or unwillingness to provide written informed consent.\n* Inability to comply with study procedures or scheduled follow-up.\n* Presence of any medical, psychiatric, or cognitive condition that, in the opinion of the investigator, would interfere with study participation or interpretation of the study results.\n* Participation in another interventional clinical trial that, in the opinion of the investigator, could interfere with the objectives of this study.",{"count":434,"type":22},200,[85],"Inflammatory lung diseases, including chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF), are major causes of morbidity and mortality worldwide. Their development and progression are influenced by environmental exposures, such as cigarette smoking and air pollution, as well as genetic susceptibility. Despite advances in disease management, early diagnosis, accurate differential diagnosis, personalized treatment, and continuous monitoring remain significant clinical challenges.\n\nThis project aims to improve the management of inflammatory lung diseases through the development and validation of innovative diagnostic, monitoring, and therapeutic approaches. The study will identify and validate multi-omics biomarkers for the differential diagnosis and prognosis of COPD, IPF, and related respiratory diseases, using machine learning techniques to develop diagnostic and prognostic biochips. Environmental determinants, including indoor and outdoor exposome factors, will be assessed to better understand their contribution to pulmonary inflammation and disease progression. The project will also develop nanotechnology-based therapeutic formulations combined with precision inhalation devices and integrate a telemedicine platform for real-time monitoring of clinical and environmental data, enabling the early detection of exacerbations and supporting personalized disease management.\n\nThe expected outcomes include improved diagnostic accuracy, enhanced risk stratification, personalized therapeutic strategies, reduced disease exacerbations, and improved quality of life for patients with inflammatory lung diseases.",[27,438],"Idiopathic Pulmonary Fibrosis",[32,90,440],"IPF","2026-07-21",{"date":417,"type":37},{"date":155,"type":22},{"date":445,"type":22},"2027-11-13",{"name":447,"class":44},"Fondazione Don Carlo Gnocchi ETS",{"id":449,"slug":450,"hasResults":12,"nctId":451,"briefTitle":452,"officialTitle":453,"acronym":4,"eligibilityCriteria":454,"healthyVolunteers":17,"sex":18,"minAge":138,"maxAge":455,"enrollmentInfo":456,"targetDuration":4,"studyType":57,"phases":458,"briefSummary":459,"conditions":460,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":461,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":467,"locationsCount":306},"100615126","phase-1-a-study-of-bbt002-in-healthy-volunteers-hvs-and-in-patients-with-chronic-obstructive-pulmonary-disease-copd-100615126","NCT07288554","A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Obstructive Pulmonary Disease (COPD)","A Randomized, Double-Blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT002 in Healthy Volunteers and Participants With Chronic Obstructive Pulmonary Disease (COPD)","Inclusion Criteria:( A\\&B)\n\n1. Age of 18-65 years (HVs), 35-75 years (patients)\n2. Body mass index between 18-32 kg\u002Fm², capped at 120 kg\n3. Negative pregnancy tests for women of childbearing potential\n4. Willingness to refrain from alcohol consumption for 24 hours prior to each study visit\n5. Non-smokers, healthy current smokers (≤5 cigarettes\u002Fday), or ex-smokers\n6. Adequate contraception use (for men and women of childbearing potential)\n7. No clinically significant abnormalities or history of relevant diseases\n\nKey Inclusion Criteria (Part B only)\n\n1. Documented history of COPD with a post-bronchodilator FEV1\u002FFVC \\\u003C 0.70\n2. FEV1 ≥ 30% and FEV1\\\u003C80% predicted at screening.\n\nExclusion Criteria:( part A \\& B)\n\n1. Positive viral serology for human immunodeficiency virus (HlV), hepatitis C virus (HCV), or hepatitis B (HBV)\n2. Immunodeficiencies, autoimmune diseases, or cancer, history of conditions predisposing to infections\n3. History of major metabolic, dermatological, liver, kidney, hematological or other significant disorders\n4. Clinically relevant abnormal lab results, including low blood counts, liver enzymes, or abnormal kidney function\n5. Positive drug\u002Falcohol tests or abnormal vital signs at screening or Day -1\n6. Abnormal Electrocardiogram(ECG) findings\n7. History of drug\u002Falcohol abuse in the past 2 years\n8. History of severe allergic reactions or hypersensitivity\n\nKey Exclusion Criteria for (Part B only)\n\n1. Current diagnosis of other significant pulmonary disease\n2. Significant or unstable cardiovascular diseases\n3. Recent clinically significant infection\n4. Inability to perform spirometry","75 Years",{"count":457,"type":22},68,[59],"This study is a randomized, double-Blind, placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT002 in Healthy Volunteers and Participants with Chronic Obstructive Pulmonary Disease (COPD).",[27],{"date":462,"type":37},"2026-07-22",{"date":464,"type":37},"2025-09-05",{"date":466,"type":22},"2027-05-30",{"name":468,"class":73},"Bambusa Therapeutics",{"id":470,"slug":471,"hasResults":12,"nctId":472,"briefTitle":473,"officialTitle":473,"acronym":4,"eligibilityCriteria":474,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":54,"enrollmentInfo":475,"targetDuration":4,"studyType":57,"phases":476,"briefSummary":477,"conditions":478,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":479,"lastUpdatePostDateStruct":480,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":74},"100588864","phase-1-regend001-autologous-basal-layer-stem-cell-transplantation-for-chronic-obstructive-pulmonary-disease-copd-a-translational-application-study-100588864","NCT06946953","REGEND001 Autologous Basal Layer Stem Cell Transplantation for Chronic Obstructive Pulmonary Disease (COPD): A Translational Application Study","Inclusion Criteria:\n\n1. Diagnosed with COPD according to the 2021 Global Initiative for Chronic Obstructive Lung Disease (GOLD);\n2. Post-bronchodilator FEV1\u002FFVC \\\u003C70%;\n3. DLCO ≥20% and \\\u003C80% of predicted value.\n\nExclusion Criteria:\n\n1. Pregnant, breastfeeding, or planning to become pregnant within 1 year after treatment (or male participants planning for their spouse to become pregnant);\n2. Positive for syphilis (TP-Ab), HIV, hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibodies;\n3. Current or past history of malignancy.",{"count":141,"type":22},[59,60],"This clinical trial aims to evaluate the safety and efficacy of REGEND001, an autologous bronchial basal cell therapy, for the treatment of Chronic Obstructive Pulmonary Disease (COPD). COPD is a chronic respiratory condition characterized by persistent airflow limitation and impaired lung function, leading to significant morbidity and mortality worldwide. Current treatments primarily focus on symptom management and have limited impact on disease progression or survival. This study proposes a novel approach using autologous bronchial basal cells, which have demonstrated the potential to repair damaged lung tissue and improve lung function in preclinical studies. The therapy involves the collection of bronchial basal cells via bronchial brushing, followed by their expansion and reintroduction into the patient's lungs via bronchoscopic infusion. The primary objective is to assess the improvement in lung diffusion capacity (DLCO), with secondary endpoints including changes in lung ventilation function (FEV1, FVC) and quality of life (CAT score). The study will also monitor safety, including the incidence of adverse events. Eligible participants are COPD patients aged 40-80 with moderate to severe disease. The trial includes a screening phase, cell collection, transplantation, and follow-up assessments at 4 and 24 weeks post-treatment. This study represents a promising advancement in regenerative medicine for COPD, offering a potential therapeutic option that addresses the underlying structural damage in the lungs.",[27],"2026-07-18",{"date":441,"type":37},{"date":482,"type":37},"2025-03-23",{"date":484,"type":22},"2029-12-31",{"name":486,"class":44},"Ruijin Hospital",{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":491,"acronym":4,"eligibilityCriteria":492,"healthyVolunteers":17,"sex":18,"minAge":53,"maxAge":54,"enrollmentInfo":493,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":495,"conditions":496,"keywords":497,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":502,"lastUpdatePostDateStruct":503,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":509,"locationsCount":45},"100566302","exploring-the-diagnostic-performance-of-dynamic-chest-radiology-in-chronic-obstructive-pulmonary-disease-100566302","NCT06653413","Exploring the Diagnostic Performance of Dynamic Chest Radiology in Chronic Obstructive Pulmonary Disease","Inclusion Criteria:\n\n\\- COPD group: (1) Patients ≥30 years of age and ≤ 80 years of age who meet the 2023 GOLD Guidelines for the Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease, i.e., anyone who complains of dyspnea, chronic cough or sputum, a history of recurrent lower respiratory infection and\u002For exposure to disease risk factors, Moreover, pulmonary function examination indicated that FEV1\u002FFVC \\\u003C0.7 after bronchodilator was used to confirm COPD. FEV1%pred is used to determine the severity of airflow obstruction: Grade GOLD 1 (mild) : FEV1%pred ≥ 80%, Grade GOLD2 (moderate) : 50% ≤ FEV1%pred \\\u003C 80%, grade GOLD3 (severe) : 30% ≤ FEV1%pred \\\u003C 50%, GOLD4 grade (extremely severe) : FEV1%pred \\\u003C 30%; (2) Signing informed consent; (3) Can cooperate with the completion of dynamic chest X-ray (complete dynamic chest X-ray positioning for 20 seconds, during which calm breathing, hard breathing, can hold breath for at least 7 seconds).\n\nNormal Group: (1) Age ≥30 years old and ≤ 80 years old; (2) Normal pulmonary ventilation function; (3) Exclude chronic airway diseases (such as COPD, asthma, bronchiectasis, etc.); (4) Signing informed consent; (5) Can cooperate with the completion of dynamic chest X-ray (complete dynamic chest X-ray positioning for 20 seconds, during which calm breathing, hard breathing, can hold breath for at least 7 seconds).\n\nExclusion Criteria:\n\n* COPD group: (1) A history of cancer, lung surgery, other lung diseases (such as pneumonia, active tuberculosis, severe bronchiectasis); (2) Combined with muscle-related diseases such as myasthenia gravis or wasting diseases that affect muscle mass such as severe hyperthyroidism and advanced malignant diseases; (3) Pregnant or lactating women; (4) Significant radiation exposure (dose \\>10mSv) was involved in the 12 months prior to study participation. Normal Group: (1) Have acute or chronic cardiopulmonary disease in the past, abnormal lung physical examination and lung imaging examination in the past, and have a history of infectious diseases within the past 1 month; (2) Pregnant or lactating women; (3) Significant radiation exposure (dose \\>10mSv) was involved in the 12 months prior to study participation.",{"count":494,"type":22},2500,"The prevalence of chronic obstructive pulmonary disease (COPD) is on the rise, leading to an increasing economic and social burden. Currently, the diagnosis and staging of COPD heavily rely on pulmonary function testing. However, limitations such as patient cooperation and comorbidities can hinder accurate diagnosis. In situations like a respiratory pandemic, pulmonary function testing may not be feasible. Dynamic chest radiography has emerged as a promising area of research due to its quick procedure, high patient cooperation, low risk, minimal radiation exposure, and reduced direct contact. Recent clinical studies have started to explore the relationship between dynamic chest X-ray measurements and lung function parameters. However, there is a noticeable scarcity of research focusing on the use of dynamic chest X-ray in aiding the diagnosis of COPD, particularly in Chinese populations where cohort data is lacking. Consequently, there is a pressing need to investigate the correlation between various dynamic chest radiograph parameters and lung function indicators, as well as their potential diagnostic value in COPD.",[27],[498,499,500,501],"Chronic obstructive pulmonary disease","Dynamic chest radiology","Pulmonary function test","Diagnosis","2026-07-17",{"date":504,"type":37},"2026-07-20",{"date":506,"type":37},"2024-01-01",{"date":508,"type":22},"2027-12-30",{"name":510,"class":44},"Nanfang Hospital, Southern Medical University",{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":4,"eligibilityCriteria":517,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":518,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":520,"conditions":521,"keywords":522,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":529,"startDateStruct":530,"completionDateStruct":532,"leadSponsor":533,"locationsCount":45},"100620085","functional-social-support-in-copd-self-management-100620085","NCT07353034","Functional Social Support in COPD Self-Management","Examining the Role of Functional Social Support Subtypes for Self-Management Capacity Among Individuals With COPD","Inclusion Criteria:\n\n* Age ≥40\n* Self-reported COPD diagnosis or treatment\n* English-speaking\n* Internet access\n\nExclusion Criteria:\n\n* History of psychosis or severe mental illness\n* Ongoing substance abuse\n* Other chronic respiratory conditions (e.g., lung cancer, asthma)",{"count":519,"type":22},111,"This observational study aims to examine how different types of functional social support (emotional\u002Finformational, tangible, affectionate, and positive social interaction) predict self-management capacity among individuals with chronic obstructive pulmonary disease (COPD). The study includes a quantitative cross-sectional survey and qualitative semi-structured interviews (N=20) to explore barriers and facilitators to adequate social support. Findings will inform the development of targeted self-management interventions for COPD patients.",[27],[523,524,525,526,527],"Social Support","Self-Management Capacity","Chronic Disease Management","Behavioral Health","Psychosocial Support","2026-07-16",{"date":502,"type":37},{"date":531,"type":37},"2025-09-26",{"date":504,"type":22},{"name":534,"class":44},"Medical University of South Carolina",{"id":536,"slug":537,"hasResults":12,"nctId":538,"briefTitle":539,"officialTitle":540,"acronym":4,"eligibilityCriteria":541,"healthyVolunteers":12,"sex":18,"minAge":138,"maxAge":4,"enrollmentInfo":542,"targetDuration":4,"studyType":57,"phases":544,"briefSummary":545,"conditions":546,"keywords":548,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":551,"lastUpdatePostDateStruct":552,"startDateStruct":553,"completionDateStruct":554,"leadSponsor":556,"locationsCount":4},"100647510","copd-ptb-screening-trial-in-henan-china-100647510","NCT07706972","COPD-PTB Screening Trial in Henan, China","Epidemiological Status and Intervention Technologies for COPD and Pulmonary Tuberculosis Comorbidity in Primary Care Settings in Henan Province, China","Inclusion Criteria:\n\n1. aged 18 years or older;\n2. residence in the local area for at least six months;\n3. providing written informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. inability to provide informed consent or complete the questionnaire;\n2. contraindications to CT scanning;\n3. current pregnancy.",{"count":543,"type":22},25000,[85],"The goal of this trial is to evaluate the effectiveness of an active case-finding (ACF) strategy for detecting pulmonary tuberculosis (PTB) among patients with chronic obstructive pulmonary disease (COPD) in primary care settings in Henan Province, China. It will also assess the epidemiological status of COPD-PTB comorbidity in this population and evaluate the feasibility of the ACF strategy in real-world primary care settings.\n\nThis is a stepped-wedge cluster randomized controlled trial. Specifically, the intervention group will receive the ACF strategy in Year 1, Year 2, and Year 3, while the control group will receive routine follow-up care in Year 1 and Year 2, and will transition to receive the ACF intervention in Year 3. All clusters will eventually receive the ACF intervention.\n\nThe main questions it aims to answer are:\n\nDoes the ACF strategy decrease the prevalence of PTB among COPD patients compared with routine passive case-finding? What are the current prevalence and epidemiological characteristics of COPD-PTB comorbidity in primary care settings in Henan Province?\n\nParticipants will:\n\nReceive ACF screening during their routine COPD follow-up visits in the intervention phase.\n\nContinue their usual COPD care as prescribed by their healthcare providers. If diagnosed with PTB through ACF screening, participants will be referred to designated hospitals for treatment in accordance with the national standardized tuberculosis treatment protocol.",[27,547],"TB - Tuberculosis",[90,549,550],"TB","active case-finding strategy","2026-07-15",{"date":528,"type":37},{"date":504,"type":22},{"date":555,"type":22},"2029-06-30",{"name":557,"class":44},"Henan Provincial People's Hospital",{"id":559,"slug":560,"hasResults":12,"nctId":561,"briefTitle":562,"officialTitle":563,"acronym":4,"eligibilityCriteria":564,"healthyVolunteers":12,"sex":18,"minAge":138,"maxAge":4,"enrollmentInfo":565,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":566,"conditions":567,"keywords":569,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":578,"startDateStruct":580,"completionDateStruct":581,"leadSponsor":582,"locationsCount":4},"100646422","red-blood-cell-and-platelet-indices-for-predicting-outcomes-in-acute-exacerbations-of-copd-100646422","NCT07693127","Red Blood Cell and Platelet Indices for Predicting Outcomes in Acute Exacerbations of COPD","Assessment of Red Blood Cell and Platelet Indices in Predicting Outcome in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease","Inclusion Criteria:\n\n* Patients above 18 years admitted to the department with AECOPD defined as an event characterized by increased dyspnea and\u002For cough and sputum that worsens in ≤14 days.\n\nExclusion Criteria:\n\n* Primary reason for admission other than AECOPD.\n* The patient has a diagnosis of connective tissue disorder, inflammatory bowel disease, or hematological system diseases (such as malignancy, thalassemia, hemolytic anemia).",{"count":169,"type":22},"The purpose of this study is to evaluate if standard, easily accessible blood tests can help doctors predict the severity and outcomes of sudden flare-ups in patients with Chronic Obstructive Pulmonary Disease (COPD).\n\nWhen a patient's COPD suddenly worsens, an event called an acute exacerbation, it can lead to serious health complications, breathing difficulties, and hospitalization. Currently, doctors need simple and cost-effective ways to figure out early on which patients are at the highest risk for severe complications.\n\nThis observational study will focus on specific components of a routine Complete Blood Count (CBC) test. Researchers will look at the size, volume, and variation of red blood cells (such as Red Cell Distribution Width, or RDW) and platelets. Both red blood cells and platelets are known to be affected by the body's systemic inflammatory response during a severe COPD flare-up.\n\nParticipants will include adults over 18 years old who are admitted to the hospital for an acute exacerbation of COPD. As part of the study, researchers will collect and analyze routine clinical data, including:\n\n* Medical history and physical examination findings (including dyspnea severity).\n* Standard laboratory blood tests (evaluating red blood cells, platelets, kidney and liver function, and inflammation markers).\n* Arterial blood gas levels.\n* Pulmonary function tests (breathing tests to measure lung capacity).\n* High-resolution computed tomography (HRCT) chest scans.\n\nBy analyzing this information, the study aims to determine if red blood cell and platelet indices can accurately predict important clinical outcomes. These outcomes include the need for Intensive Care Unit (ICU) admission, the need for a mechanical ventilator (breathing machine), the total length of the hospital stay, and in-hospital mortality. Identifying reliable biomarkers could help healthcare providers make faster, more targeted treatment decisions for COPD patients.",[388,27,568],"AECOPD",[570,571,572,573,574,32,575,576],"Red Blood Cell Indices","Platelet Indices","Red Cell Distribution Width (RDW)","Mean Platelet Volume (MPV)","Platelet Distribution Width (PDW)","Prognosis","Systemic Inflammation","2026-07-03",{"date":579,"type":37},"2026-07-09",{"date":396,"type":22},{"date":398,"type":22},{"name":400,"class":44},{"id":584,"slug":585,"hasResults":12,"nctId":586,"briefTitle":587,"officialTitle":588,"acronym":4,"eligibilityCriteria":589,"healthyVolunteers":12,"sex":18,"minAge":138,"maxAge":54,"enrollmentInfo":590,"targetDuration":4,"studyType":57,"phases":592,"briefSummary":593,"conditions":594,"keywords":596,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":599,"lastUpdatePostDateStruct":600,"startDateStruct":602,"completionDateStruct":604,"leadSponsor":605,"locationsCount":45},"100627330","comparing-ultrasonic-and-conventional-spirometry-in-chronic-respiratory-disease-100627330","NCT07447232","Comparing Ultrasonic and Conventional Spirometry in Chronic Respiratory Disease","A Comparative Study of Ultrasonic and Conventional Spirometers in Patients With Chronic Respiratory Diseases","Inclusion Criteria:\n\n* Adults aged 18 to 80 years.\n* Diagnosed with a chronic respiratory disease (e.g., COPD, asthma, bronchiectasis, or interstitial lung disease).\n* Willing to follow the instructions for using the ultrasonic spirometer.\n* Clinically stable and able to understand the study purpose and procedures, and who provide informed consent.\n\nExclusion Criteria:\n\n* Individuals who, after explanation, are still unable to properly perform the ultrasonic spirometry procedure.\n* Individuals who, after explanation, refuse to participate in the study.\n* Patients with unstable vital signs.\n* Pregnant or suspected pregnant women.",{"count":591,"type":22},100,[85],"This study compares a handheld ultrasonic spirometer with a standard hospital spirometer in adults with chronic respiratory diseases. Each participant will complete lung function tests using both devices. The study aims to determine whether the ultrasonic device provides accurate and reliable measurements for use in clinical or home settings.",[27,595],"Spirometry",[27,595,597,598],"Ultrasonic Flow Sensor","Pulmonary Function Test","2026-07-01",{"date":601,"type":37},"2026-07-02",{"date":603,"type":37},"2026-06-29",{"date":239,"type":22},{"name":606,"class":44},"Fu Jen Catholic University",{"id":608,"slug":609,"hasResults":12,"nctId":610,"briefTitle":611,"officialTitle":611,"acronym":612,"eligibilityCriteria":613,"healthyVolunteers":12,"sex":18,"minAge":138,"maxAge":455,"enrollmentInfo":614,"targetDuration":4,"studyType":57,"phases":616,"briefSummary":617,"conditions":618,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":621,"lastUpdatePostDateStruct":622,"startDateStruct":623,"completionDateStruct":624,"leadSponsor":626,"locationsCount":4},"100645394","division-of-the-interlobar-fissure-in-patients-who-do-not-respond-to-endobronchial-lung-volume-reduction-100645394","NCT07682168","DIVision of the Interlobar Fissure in Patients Who Do Not Respond to Endobronchial Lung Volume Reduction","DIVIDE","Inclusion criteria\n\n1. Age \\\u003C or equal 75 years\n2. Stable COPD with less than or equal to 10mg prednisolone daily\n3. Nonsmoking for 3 months prior to screening and willing to not smoke during the study duration\n4. Willing and able to complete protocol required study follow-up assessments and procedures\n5. Fit for thoracoscopy under general anaesthesia (surgical and anaesthetic assessment)\n6. Recent (\\\u003C 18 months) endobronchial lung volume reduction (EBLVR) and lack of response defined by:\n\n   1. Persistent symptomatic dyspnoea (mMRC \\>2) which in the patient's view is no better than baseline\n   2. Absence of target lobar collapse with any residual aeration apparent on imaging\n   3. Persistence of (6a) and (6b) following post procedure StratX CT analysis and revisional bronchoscopy.\n\nExclusion criteria\n\n1. Fissure completeness \\\u003C90% on pre EBLVR StratX (i.e less than 10% of fissure to be divided)\n2. Chartis positive for collateral ventilation or not performed\u002Fnot satisfactory at initial EBLVR\n3. Quantitative perfusion of target lobe \\>25% of total on SPECT assessment.\n4. Previous lung surgery or pleurodesis on the target side for LVR.\n5. Clinically significant bronchiectasis -greater than 4 tablespoons mucus per day.\n6. More than 3 COPD exacerbation episodes in the last year.\n7. Evidence of hypercapnia (pCO2 \\>7KPa) - ABG to be performed on admission for index procedure\n8. Clear evidence of pulmonary hypertension (systolic pulmonary arterial pressure \\>45mmHg) or evidence or right ventricular dysfunction as determined by a recent echocardiogram (\\\u003C12mo)\n9. Left ventricular ejection fraction (LVEF) less than 40% as determined by a recent echocardiogram (\\\u003C12mo)\n10. Myocardial infarction within 6 months of screening.\n11. Unable to safely discontinue anticoagulants or platelet activity inhibitors for 7 days.",{"count":615,"type":22},15,[85],"Surgical division of fissure is hypothesized to be safe and feasible. However, there is no preparatory study to test this hypothesis. It is logically expected that morbidity from the procedure could be less than standard LVRS and in preparation to a side-to-side trial of fissure division versus standard LVRS, a safety and feasibility study is required to test this hypothesis and inform future trial design.",[27,619,620],"Emphysema","Lung Volume Reduction Surgery","2026-06-26",{"date":601,"type":37},{"date":396,"type":22},{"date":625,"type":22},"2028-01",{"name":627,"class":628},"Rocco Bilancia","OTHER_GOV",{"id":630,"slug":631,"hasResults":12,"nctId":632,"briefTitle":633,"officialTitle":634,"acronym":635,"eligibilityCriteria":636,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":54,"enrollmentInfo":637,"targetDuration":4,"studyType":57,"phases":639,"briefSummary":640,"conditions":641,"keywords":642,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":643,"lastUpdatePostDateStruct":644,"startDateStruct":646,"completionDateStruct":648,"leadSponsor":650,"locationsCount":651},"100583974","phase-3-a-study-to-investigate-the-efficacy-and-safety-of-tezepelumab-in-adult-participants-with-moderate-to-very-severe-copd-d5241c00006-100583974","NCT06883305","A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)","A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease","EMBARK","Inclusion Criteria:\n\n1. ≥40 to ≤80 years old\n2. COPD diagnosis ≥1 year,\n3. Post-BD FEV1 ≥ 20% and ≤ 70% PN, FEV1\u002FFVC \\\u003C0.70 at screening\n4. Triple (ICS+LABA+LAMA) or dual inhaled COPD therapy, if triple therapy is considered not appropriate, ≥3 consecutive months prior to V1\n5. ≥2 moderate or ≥1 severe COPD exacerbations in the prior year; At least 1 of 2 moderate exacerbations must require the use of systemic corticosteroids. At least one of the previous exacerbations should be confirmed to have occurred while the participant was on triple or dual inhaled maintenance therapy\n6. EOS ≥ 150 cells\u002FμL during screening\n7. CAT ≥15 at screening\n8. Former or current smokers ≥10 pack-years\n\nExclusion Criteria:\n\n1. Clin. important pulmonary disease or radiological findings suggestive of a respiratory disease other than COPD\n2. Asthma, incl. pediatric, or ACOS\n3. Any unstable disorder that can impact participants safety or study outcomes\n4. Tuberculosis requiring treatment within 12 months prior V2\n5. Malignancies current or past\n\n   Concomitant therapies:\n   * Macrolides (less than 6 months)\n   * Systemic immuno-suppressive, -modulating medications\n6. LTOT \\>4.0 L\u002Fmin or O2 saturation \\\u003C89% despite LTOT",{"count":638,"type":22},990,[290],"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)",[27],[90,115,116,117,118],"2026-06-23",{"date":645,"type":37},"2026-06-24",{"date":647,"type":37},"2025-03-18",{"date":649,"type":22},"2029-06-05",{"name":128,"class":73},301,{"id":653,"slug":654,"hasResults":12,"nctId":655,"briefTitle":656,"officialTitle":634,"acronym":657,"eligibilityCriteria":636,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":54,"enrollmentInfo":658,"targetDuration":4,"studyType":57,"phases":659,"briefSummary":640,"conditions":660,"keywords":661,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":643,"lastUpdatePostDateStruct":662,"startDateStruct":663,"completionDateStruct":665,"leadSponsor":666,"locationsCount":667},"100583587","phase-3-a-study-to-investigate-the-efficacy-and-safety-of-tezepelumab-in-adult-participants-with-moderate-to-very-severe-copd-d5241c00007-100583587","NCT06878261","A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)","JOURNEY",{"count":638,"type":22},[290],[27],[90,115,116,117,118],{"date":645,"type":37},{"date":664,"type":37},"2025-03-25",{"date":649,"type":22},{"name":128,"class":73},268,"Chronic Obstructive Pulmonary Disease, COPD"]